Uniqure NV
NASDAQ:QURE
Intrinsic Value
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. [ Read More ]
The intrinsic value of one QURE stock under the Base Case scenario is 14.18 USD. Compared to the current market price of 4.56 USD, Uniqure NV is Undervalued by 68%.
Valuation Backtest
Uniqure NV
Run backtest to discover the historical profit from buying and selling QURE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Uniqure NV
Current Assets | 651.9m |
Cash & Short-Term Investments | 617.9m |
Receivables | 4.2m |
Other Current Assets | 29.8m |
Non-Current Assets | 179.8m |
PP&E | 75.3m |
Intangibles | 86.9m |
Other Non-Current Assets | 17.6m |
Current Liabilities | 73.7m |
Accounts Payable | 6.6m |
Accrued Liabilities | 38.9m |
Other Current Liabilities | 28.2m |
Non-Current Liabilities | 550.3m |
Long-Term Debt | 496m |
Other Non-Current Liabilities | 54.4m |
Earnings Waterfall
Uniqure NV
Revenue
|
15.8m
USD
|
Cost of Revenue
|
-13.6m
USD
|
Gross Profit
|
2.2m
USD
|
Operating Expenses
|
-285.1m
USD
|
Operating Income
|
-282.9m
USD
|
Other Expenses
|
-25.6m
USD
|
Net Income
|
-308.5m
USD
|
Free Cash Flow Analysis
Uniqure NV
QURE Profitability Score
Profitability Due Diligence
Uniqure NV's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Uniqure NV's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
QURE Solvency Score
Solvency Due Diligence
Uniqure NV's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Uniqure NV's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QURE Price Targets Summary
Uniqure NV
According to Wall Street analysts, the average 1-year price target for QURE is 21.26 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.
Ownership
QURE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
QURE Price
Uniqure NV
Average Annual Return | -15.79% |
Standard Deviation of Annual Returns | 34.64% |
Max Drawdown | -94% |
Market Capitalization | 218.1m USD |
Shares Outstanding | 47 840 000 |
Percentage of Shares Shorted | 6.05% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact
IPO
Employees
Officers
The intrinsic value of one QURE stock under the Base Case scenario is 14.18 USD.
Compared to the current market price of 4.56 USD, Uniqure NV is Undervalued by 68%.